Patient-specific neoepitope–Major Histocompatibility Complex class II complex (Neoepitope-MHC II)

Patient-specific neoepitope–Major Histocompatibility Complex (MHC) class II complexes are molecular assemblies consisting of a tumor-specific mutated peptide bound to an MHC class II molecule. These complexes are primarily expressed on the surface of professional antigen-presenting cells, such as dendritic cells, and occasionally on tumor cells themselves. Their fundamental biological role is to present unique, mutation-derived antigens to CD4+ T lymphocytes, thereby initiating and modulating the adaptive immune response against cancer (Alspach et al., 2019, Nature). Because these neoepitopes arise from somatic mutations unique to an individual's tumor, they are not subject to central tolerance, allowing for high-avidity T-cell recognition (Sahin et al., 2017, Nature). In clinical practice, these complexes serve as the primary target for personalized cancer vaccines and adoptive T-cell therapies designed to elicit a bespoke immune attack (Ott et al., 2017, Nature). Therapeutic success often depends on the accurate prediction of peptide-MHC binding affinity and the subsequent expansion of neoantigen-specific T-cell populations. However, challenges such as tumor-mediated MHC downregulation and the logistical complexity of patient-specific manufacturing remain significant hurdles in the field (Xie et al., 2023, Frontiers in Immunology).

Other names

Neoantigen-MHC II complexTumor-specific antigen-HLA class II complexpMHC II complexNeoAg-MHC II

The mechanism of action involves the therapeutic induction or enhancement of T-cell responses against tumor-specific neoepitopes. Vaccines (mRNA, DNA, or peptide-based) deliver the neoantigen sequence to antigen-presenting cells, which then process and present the neoepitope on MHC class II molecules to activate CD4+ T helper cells (Sahin et al., 2017, Nature). Alternatively, adoptive cell therapies utilize T cells engineered with receptors (TCRs) that specifically recognize the patient's unique neoepitope-MHC II complex, leading to direct tumor cell recognition or the provision of essential cytokines to support cytotoxic CD8+ T-cell activity (Alspach et al., 2019, Nature).